Clinical Trial Detail

NCT ID NCT02073994
Title Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Agios Pharmaceuticals, Inc.
Indications

Advanced Solid Tumor

Therapies

Ivosidenib

Age Groups: adult

Additional content available in CKB BOOST